Karuna’s schiz­o­phre­nia drug clears an­oth­er PhI­II as biotech seeks 2024 launch

Karuna Ther­a­peu­tics said its in­ves­ti­ga­tion­al schiz­o­phre­nia treat­ment cleared the bar in an­oth­er Phase III clin­i­cal tri­al, which the biotech hopes will open the doors for a new class of med­ica­tion for the mil­lions of peo­ple liv­ing with the dis­or­der as it tees up a mid-2023 ap­proval re­quest.

The Boston biotech’s KarXT drug showed a sta­tis­ti­cal­ly sig­nif­i­cant and clin­i­cal­ly mean­ing­ful re­duc­tion in symp­toms com­pared to place­bo on the main study goal in pa­tients with schiz­o­phre­nia, Karuna said be­fore Mon­day’s open­ing bell. The de­sign of the 256-pa­tient Phase III EMER­GENT-3 was es­sen­tial­ly a “car­bon copy” of the com­pa­ny’s two oth­er Phase III and Phase II stud­ies of the drug, CEO and pres­i­dent Bill Meury told End­points News on Sun­day af­ter­noon, in a pre­view of the da­ta drop.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN